Study S002616

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

ClinicalTrials.gov record

Registration

Registration: NCT02176681
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 70
Start: 2014-06
Primary completion: 2017-10
Lead sponsor: University Hospital, Strasbourg, France
Conditions: Haemodialyzed, Type 2 Diabetes
Interventions: DRUG:Vildagliptin (Galvus); DRUG:Insulin
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2013-004737-33

Registered primary outcomes

Mean glucose value of CGM [M] to be averaged from day 2 and day 3 of CGM [up to day 3]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.